Aspergillosis: Causes, Symptoms, Treatment & Prevention

Aspergillosis refers to tissue invasion, allergic inflammation, or chronic colonization driven by Aspergillus species after conidia deposit on respiratory mucosa. Immunocompetent people usually clear spores without disease; when alveolar macrophage and neutrophil killing fail—as in chemotherapy-induced neutropenia, transplant conditioning, or high-dose glucocorticoids—angioinvasive hyphae create necrotising lung lesions that can spread haematogenously. A parallel pathway is hypersensitivity: ABPA reflects a polyclonal IgE-rich response to airway mould antigen without requisite tissue invasion, producing eosinophilic inflammation and bronchiectasis in at-risk airway disease.

Chronic pulmonary aspergillosis occupies a middle tempo—months of cough, fatigue, and cavitation—often against a backdrop of prior lung cancer resections, emphysema, or healed granulomatous infection. Acute obstructing bronchitis or sinusitis variants exist but lung syndromes dominate acute inpatient concerns alongside disseminated disease involving the CNS or skin in the most immunosuppressed cohorts.

↔On a small screen, swipe or scroll sideways to see the full table.

Severity scoring systems exist for research (for example EORTC/MSG host factors), but ward teams usually operationalise “probable vs proven” labels from combined microbiology, imaging, and biopsy data rather than a single number.

Typical

• Pleuritic pain, cough productive of mucus or blood, and progressive exertional limitation.
• Low-grade or spiking fevers in IPA—may be masked by corticosteroids.
• Wheeze and tenacious secretions in ABPA flares.

Atypical or easy to misread

• “Ventilator-associated pneumonia” phenotype in ICU with minimal secretions but falling compliance.
• Isolated sinus headache or facial pain in a neutropenic patient—sinus IPA can precede lung clearance failure.
• Fatigue-predominant chronic illness without florid fever in cavitary CPA.

Older adults and steroid-covered patients may lack classic fever; trajectory of oxygen requirement often tells the story earlier than temperature curves.

Exposure is environmental—mouldy compost, construction dust, water-damaged wards—superimposed on impaired immunity. Medication risks include prolonged neutropenia after leukemia therapy, CD4 suppression, calcineurin inhibitors, TNF antagonists, and prolonged high-dose steroids. Structural lung disease provides niches for chronic colonisation; intensive care-associated IPA increasingly links to influenza or bacterial superinfection and immune-modulating bundles rather than classic chemotherapy alone.

Modifiable vs fixed (clinical shorthand)

• Modifiable where safe: steroid dose taper plans with specialist agreement, shortening neutropenia when feasible, holding non-essential immunomodulators during active mould infection.
• Fixed context: underlying COPD or airway disease, graft-versus-host biology, graft type—requires vigilance rather than prevention of spore contact.

Clinical assessment

Document neutrophil count trends, steroid exposure, transplant day, oxygen trajectory, antecedent viral illness, and any prior azole prophylaxis—each reshapes pre-test probability.

Laboratory investigations

• Complete blood count with differential (eosinophils in ABPA).
• Galactomannan antigen (serum or BAL) with institutional cut-offs; beta-d-glucan may support some invasive mould contexts but is non-specific.
• CRP and lactate trends to contextualise sepsis versus isolated fever.

Imaging

• Chest X-ray for baseline—often non-specific early.
• Thin-cut CT scan of chest for nodule character, halo/air-crescent signs, infarcts, cavities.

Procedures & criteria

Bronchoscopy with BAL supports galactomannan from alveolar fluid and culture; transbronchial or CT-guided biopsy upgrades diagnostic certainty when bleeding risk permits. Specimen collection timing, lab pre-notification, and transport stability protect diagnostic yield. Microscopy showing dichotomously branching hyphae in sterile tissue is definitive. International consensus definitions classify proven, probable, and possible invasive fungal disease—use the version your laboratory and MDT cite for audit and antifungal stewardship.

• Suspected IPA in high-risk host + compatible CT: notify infectious diseases; initiate mold-active therapy per protocol while arranging BAL/biopsy unless contraindicated.
• Low pre-test probability but unexplained deterioration: repeat imaging at 48–72 h; early non-resolution on antibacterial therapy should lower threshold for antifungal extension.
• ABPA flare: confirm eosinophilic pattern and exclude active infection mimics; coordinate oral steroid bursts with antifungal cover and monitor peak flow or spirometry per clinic.
• Chronic cavitation: baseline CT density, 6–12 week microbiology review, oral triazole adherence checks, and surgery referral only via MDT.
• Azole resistance suspected (refractory despite adequate exposure): arrange referral for susceptibility testing; consider liposomal amphotericin B or combination regimens per guideline addenda—not ad hoc dose-doubling alone.

• Bacterial or viral pneumonia, including mixed ICU pathogens.
• Tuberculosis or non-tuberculous mycobacteria in cavitary illness.
• Other angioinvasive moulds (for example mucormycosis)—rapidly progressive cases merit broader empiric regimens until identification.
• Malignancy with necrotic nodes masquerading as fungal nodules.

Invasive pulmonary aspergillosis

First-line therapy in most immunosuppressed adults is mould-active triazole therapy—commonly intravenous then oral voriconazole—with dose adjustments for hepatic function, drug interactions (especially cytochrome P450 substrates), and therapeutic monitoring when locally available. Refractory disease, intolerance, or known resistance triggers switch to liposomal amphotericin B, alternative azoles, or combination approaches under subspecialty guidance. Recovery of neutrophils and reduction of immunosuppression when clinically safe are disease-modifying “therapies” in their own right.

Allergic bronchopulmonary aspergillosis

Oral corticosteroids control eosinophilic inflammation; concurrent antifungal therapy lowers airway fungal burden. Intravenous methylprednisolone may appear during inpatient crises but transitions to oral regimens for maintenance. Omalizumab or other biologics occupy selected refractory cases per respiratory clinic pathways.

Chronic pulmonary aspergillosis / aspergilloma

Long-course oral triazoles stabilise many chronic cavities; massive or recurrent hemoptysis may require bronchial artery embolisation or surgery coordinated with thoracic surgeons. Observation alone suits some patients with limited symptoms and stable imaging.

Week-to-week care combines stewardship (right drug, right duration), toxicity surveillance, and clear escalation thresholds.

• Medication safety: chart QT-prolonging co-medications, sirolimus/tacrolimus levels in transplant recipients, and enzyme-inducing anticonvulsants that slash azole exposure.
• Monitoring cadence: baseline and weekly LFTs during induction are common; extend spacing per local protocol once stable. Visual symptom checks every shift during voriconazole loading.
• Follow-up windows: ABPA reviews often cluster at 4–12 weeks after steroid taper; CPA imaging can sit on 3–6 month intervals if clinically quiet.
• Failure patterns: rising oxygen requirement, enlarging cavities, or climbing galactomannan after ≥7 days of therapy should trigger MDT re-evaluation sooner than routine intervals.
• Documents & communication: record steroid exposure days, neutrophil nadirs, antifungal start times, and family decisions about aggressive versus comfort-focused paths to avoid contradictory night-team orders.
• Infection prevention: apply isolation precautions per organization policy during high-risk neutropenia or institutional mould investigation—avoid improvising airborne rooms without epidemiology input.

Deterioration cues that warrant immediate senior call

• SpO₂ down ≥3% from patient-specific baseline despite optimised oxygen therapy.
• New focal neuro deficits or thunderclap headache in a patient on therapy for IPA.
• Persistent tachycardia with narrowing pulse pressure and rising lactate after adequate fluids.

• Pleural invasion, pneumothorax, or bronchopleural fistula from necrotic parenchyma.
• Massive hemoptysis with aspergilloma or cavitary IPA.
• CNS abscess or stroke from hematogenous seeding.
• Acute kidney injury from concomitant nephrotoxins or amphotericin exposure.
• Chronic respiratory failure or pulmonary hypertension after destructive cavitary disease.

Primary prevention centres on careful immunosuppression, antifungal prophylaxis in selected hematology protocols, influenza and pneumococcal vaccination where appropriate, and air-quality vigilance on transplant wards. During hospital construction, follow facility risk assessments; counsel outpatients to avoid mold-heavy environments when neutropenic.

IPA mortality remains substantial in delayed presentations but improves when diagnosis, neutrophil recovery, and effective antifungals align. CPA behaves as a chronic illness—with functional limitation but long-term survival on suppressive therapy in many patients. ABPA flare frequency drops when inhaled therapy and mould-directed regimens stay adherent.

Subtle signals

Night shifts often notice fluctuating work of breathing or sleep disruption before formal “alert” vitals fire—pair nurse intuition with objective trends.

Psychological load

Explain that visible mould avoidance at home cannot eliminate risk; focus teaching on medication adherence, fever thresholds, and who to call.

Documentation

Record oxygen delivery device and FiO₂ equivalence, antifungal batch changes, non-chemo immunosuppressant holds, and patient-reported visual symptoms verbatim for pharmacy review.

• Respiratory rate, SpO₂, accessory muscle use, and secretion viscosity q1–4h per acuity.
• Blood pressure trends in patients on vasoactive drugs or post-embolisation.
• Strict intake/output and weight when amphotericin or nephrotoxic partners run.
• Daily sensory checks (vision, tremor) during voriconazole induction.
• Line care discipline for prolonged parenteral antifungals—organism entry often precedes a second hit.

These NCLEX-style clinical judgment practice items focus on the nursing priorities for this condition — recognise cues, escalate red flags, take safe action and evaluate outcomes (NCSBN Clinical Judgment Measurement Model) — through Priority FIRST, SATA, deterioration trends, multi-patient triage, ordered response, matrix matching and a compact cloze on the topic of the major aspergillosis syndromes (allergic bronchopulmonary aspergillosis, aspergilloma, chronic and invasive pulmonary aspergillosis), voriconazole-first stewardship in the immunocompromised and the haemoptysis / sepsis red flags.